CTSHIV: A knowledge-based system for the management of HIV-infected patients

Proceedings - Intelligent Information Systems, IIS 1997

Volumn , Issue , 1997, Pages 7-13

  Pazzani, M ^a   Iyer, R ^a   See, D ^b   Schroeder, E ^b   Tilles, J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRAL AGENTS; CLONING; DISEASES; ENCODING (SYMBOLS); EXPERT SYSTEMS; GENE ENCODING; INFORMATION USE; PATIENT TREATMENT; POLYMERASE CHAIN REACTION; VIRUSES;

ANTIVIRAL ACTIVITIES; GENETIC SEQUENCING; INTEGRASE PROTEIN; MEDICAL LITERATURES; REDUNDANT MECHANISMS; REVERSE TRANSCRIPTASES; RULE BASED EXPERT SYSTEMS; WEIGHT COMBINATION;

MEDICAL INFORMATION SYSTEMS;

EID: 85033699785     PISSN: None     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1109/IIS.1997.645169     Document Type: Conference Paper

References (19)

1. DeClercq E. Antiviral therapy for human immunodeficiency virus infections. Clin Microbiol Rev 1995,8:200-239.
2. Frost S, McLean A. Quasispecies dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS 1994,8:323-332.
3. Ho D, Moudgil D, Alan M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. 1989,321:1621-1625.
4. Holodniy M, Katzenstein D, Winters M, Mon-toya J, Shafer R, Kozal M, Ragni M, Merigan T. Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. J Acquired Immune Defic Syndr 1993,6,366-369.
5. Kahn J, Lagakos S, Richman D, Cross A, Petinelli C, Liou S, Brown M, Volberding P, Crumpacker C, Beall G, Sqacks S, Merigan T, Beltangady M, Smaldone L, Dolin R. A controlled trial comparing zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med 1992,327,581-587.
6. Schooley RT, Ramirez-Ronda C, Lange JM, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder BA, St. Clair M, Mulder JW. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group. J Infect Dis 1996,173,1354-66.
7. Zhu QY, Scarborough A, Polsky B, Chou TC. Drug combinations and effect parameters of zidovudine, stavudine, nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. AIDS Research and Human Retroviruses 1996,12,507-17.
8. Lange JM. Triple combinations: Present and future. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995, 10 Suppl l,S77-82.
9. Larder B, Darby G, Richman D. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1991,243,1731-1734.
10. Larder B, Kellam P, Kemp S. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 1991,5:137-144.
11. Larder B, Kemp S. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989,246:1155-1158.
12. Frenkel L, Wagner M, Atwood S, Cummins T, Dewhurst S. Specific, sensitive, rapid assay for HIV pol mutations associated with resistance to zidovudine and didanosine. 1995,33:342-347.
13. Jackson P. Introduction to Expert Systems. Addison-Wesley, Reading MA, 1990.
14. Pazzani M, Kibler D. The utility of knowledge in Inductive learning. Machine Learning 1992,9:57-94.
15. Ohno-Machado L, Parra E, Henry S, Tu S, Musen M. AIDS 2: A decision-support tool for decreasing physician's uncertainty regarding patient eligibility for HIV treatment protocols. Proceedings of the 17th Annual Symposium on Computer Applications in Medical Care, Washington DC, 1993, 429-433.
16. St Clair M, Martin J, Tudor W. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991,253:1557-1559.
17. Gu Z, Gao Q, Li X, Parniak M, Wainberg M. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. J Virol 1992,66,7128-7135.
18. Gu Z, Gao Q, Fang H, Parniak M, Brenner B, Wainberg M. Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. Leukemia 1994,8S1:5166-5169.
19. Richman D, Shih C, Lowy I, Rose J, Prodanovich P, GoffS, Griffin J. 20. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue culture. Proc Natl Acad Sci Usa. 1991,88,11241-11245.